AROUND THE INDUSTRY

MyOwnMed legal counsel, Goodwin Procter: The impact COVID-19 may have on our life sciences clients

“As the COVID-19 pandemic unfolds, our drug, biologic, and medical device clients conducting or planning to conduct clinical trials may be faced with challenges related to quarantines, travel limitations, site closures or access restrictions, infection transmission concerns of site research personnel and study subjects, and supply chain interruptions.” Read More Read more…

By Debbie Ferrari, 4 years4 years ago

AROUND THE INDUSTRY

Lilly slashes clinical trial activities in response to COVID-19

By Debbie Ferrari, 4 years4 years ago

AROUND THE INDUSTRY

US FDA Outlines Wishlist For Decentralized Clinical Trials

Clinical Trial Sponsors Should Consider Changing Data Collection Amid COVID-19, US FDA Says. (March 18, 2020) READ MORE …

By Debbie Ferrari, 4 years4 years ago

AROUND THE INDUSTRY

FDA: Clinical Trial Sponsors Should Consider Changing Data Collection Amid COVID-19 Response

Maintaining the safety of clinical trial participants amid COVID-19 and beyond The MyOwnMed ECOS System dovetails with the FDA’s guidance released mid-March, 2020. Let us know if your institution could benefit from a tour of the ECOS Platform.

By Debbie Ferrari, 4 years4 years ago